Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Research & Development (2017 - 2025)

Historic Research & Development for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $90.5 million.

  • Crinetics Pharmaceuticals' Research & Development rose 4613.36% to $90.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $313.6 million, marking a year-over-year increase of 4307.2%. This contributed to the annual value of $240.2 million for FY2024, which is 4250.3% up from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Research & Development is $90.5 million, which was up 4613.36% from $80.3 million recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Research & Development peaked at $90.5 million during Q3 2025, and registered a low of $17.6 million during Q1 2021.
  • Its 5-year average for Research & Development is $47.2 million, with a median of $42.2 million in 2023.
  • Its Research & Development has fluctuated over the past 5 years, first soared by 6066.88% in 2022, then surged by 2317.02% in 2023.
  • Over the past 5 years, Crinetics Pharmaceuticals' Research & Development (Quarter) stood at $24.6 million in 2021, then surged by 50.35% to $37.0 million in 2022, then grew by 23.22% to $45.6 million in 2023, then soared by 46.04% to $66.6 million in 2024, then skyrocketed by 35.9% to $90.5 million in 2025.
  • Its Research & Development stands at $90.5 million for Q3 2025, versus $80.3 million for Q2 2025 and $76.2 million for Q1 2025.